Higher risks of triple-negative breast cancer and ERBB2 enriched–like tumors among former OC users (for >5 years) and those who ceased use within the last 10 years and significant heterogeneity by disease subtype (P = .02) are in line with our findings in women with healthy weight. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.